By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Daiichi Sankyo, Inc. 

U.S. Corporate Headquarters
Two Hilton Court
Parsippany  New Jersey  07054  U.S.A.
Phone: 973-944-2600 Fax: 973-359-2645


About Daiichi Sankyo, Inc.

Daiichi Sankyo Inc., headquartered in Parsippany, New Jersey, is the U.S. subsidiary of Tokyo-based Daiichi Sankyo Co., Ltd., which is a global pharmaceutical innovator.

The headquarters company was established in 2005 from the merger of two leading Japanese pharmaceutical companies. This integration created a more robust organization that allows for continuous development of novel drugs that enrich the quality of life for patients around the world.

A central focus of Daiichi Sankyo's research and development is cardiovascular disease, including therapies for dyslipidemia, hypertension, diabetes and acute coronary syndrome. Also important to the company is the discovery of new medicines in the areas of infectious diseases, cancer, bone and joint diseases, and immune disorders.

This div will be replaced

Key Statistics

Ownership: Public

Web Site: Daiichi Sankyo, Inc.
Employees: 3,000 in the U.S.
Symbol: DSNKY



Eli Lilly 


U3 Pharma 

Company News
HTG Molecular Diagnostics And Daiichi Sankyo, Inc. (DSNKY) Complete Master Services Agreement 4/17/2017 8:21:27 AM
On a Roll: Kite Pharma (KITE) Bags $250 Million CAR-T Deal From Daiichi Sankyo, Inc. (DSNKY), Forms Joint Venture With Fosun Pharma 1/9/2017 2:30:05 PM
Daiichi Sankyo, Inc. (DSNKY) Not Proceed With Lung Cancer Study 5/31/2016 9:46:16 AM
Daiichi Sankyo Cuts-and-Pastes for 5-Year Plan: Sister Companies Daiichi Sankyo, Inc. (DSNKY) and Asubio Pharma Co., Ltd. Merge 4/1/2015 6:53:23 AM
Charleston Laboratories, Inc. And Daiichi Sankyo (4568.t) Announce Completion Of A Pharmacokinetics Study On CL-108 3/12/2015 7:25:05 AM
Daiichi Sankyo (4568.t) Release: SAVAYSA (edoxaban) Now Available In U.S. Pharmacies 2/9/2015 9:04:11 AM
Growth Concerns Loom for Daiichi Sankyo (4568.t) on Drug Warning 2/9/2015 6:24:26 AM
Daiichi Sankyo, Inc. (4568.t) Announces First Patients In Large-Scale, Multi-National Phase 3 Clinical Programs For Mirogabalin 2/4/2015 7:25:15 AM
Daiichi Sankyo, Inc. (4568.t) Announces Civil Settlement 1/9/2015 8:21:17 AM
U.S. FDA Approves Daiichi Sankyo, Inc. (4568.t)'s Once-Daily SAVAYSA™ (Edoxaban) Tablets For Reduction Of Stroke Risk In Non-Valvular Atrial Fibrillation And For The Treatment Of Venous Thromboembolism 1/9/2015 6:06:44 AM